Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Viking Therapeutics (VKTX) Misses Q1 EPS by 2c
April 28, 2021 4:47 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.19), $0.02 worse than the analyst estimate of ($0.17).
Highlights from the Quarter Ended March 31, 2021:
"During the first quarter of 2021, we continued to build on the significant progress made during 2020 with both of our thyroid hormone... More
